Icon’s (ICLR) “Underperform” Rating Reiterated at Bank of America

Bank of America reaffirmed their underperform rating on shares of Icon (NASDAQ:ICLR) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage currently has a $75.00 price target on the medical research company’s stock.

Several other equities analysts have also recently commented on the stock. UBS Group set a $220.00 target price on shares of Icon in a research report on Friday, October 24th. Barclays lifted their price objective on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Mizuho set a $216.00 target price on Icon in a research report on Friday, January 9th. Robert W. Baird set a $217.00 target price on Icon in a research note on Friday, January 9th. Finally, Leerink Partners restated a “market perform” rating and issued a $105.00 price target on shares of Icon in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $173.40.

Icon Stock Up 16.1%

ICLR stock opened at $93.00 on Thursday. Icon has a 52 week low of $66.57 and a 52 week high of $211.00. The business has a 50-day simple moving average of $175.93 and a 200 day simple moving average of $174.87. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The company has a market cap of $7.51 billion, a PE ratio of 12.58, a price-to-earnings-growth ratio of 1.95 and a beta of 1.27.

Institutional Investors Weigh In On Icon

Institutional investors have recently added to or reduced their stakes in the business. Artisan Partners Limited Partnership raised its stake in shares of Icon by 67.4% during the second quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock valued at $1,045,039,000 after acquiring an additional 2,893,946 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Icon by 26.6% in the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after purchasing an additional 975,268 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Icon by 21.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock worth $545,730,000 after purchasing an additional 650,379 shares during the last quarter. Invesco Ltd. increased its holdings in Icon by 11.1% in the third quarter. Invesco Ltd. now owns 3,427,630 shares of the medical research company’s stock valued at $599,835,000 after purchasing an additional 341,637 shares during the period. Finally, Principal Financial Group Inc. raised its position in Icon by 739.2% during the 3rd quarter. Principal Financial Group Inc. now owns 3,277,293 shares of the medical research company’s stock worth $573,526,000 after purchasing an additional 2,886,755 shares during the last quarter. 95.61% of the stock is owned by institutional investors.

More Icon News

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Some analyst support remains — Leerink Partners reaffirmed a “market perform” rating and a $105 price target, providing a floor for some investors. Leerink note
• Neutral Sentiment: ICON issued a timing update saying it is delaying release of Q4 and full‑year 2025 earnings while the internal investigation continues — the announcement is procedural but keeps uncertainty elevated until results are filed. Company update
• Negative Sentiment: Multiple law firms have opened securities‑fraud investigations and are soliciting shareholders after ICON disclosed possible revenue‑recognition issues; that legal overhang amplifies downside risk and potential remediation costs. Glancy announcement
• Negative Sentiment: Market reaction has already been severe: the initial accounting‑probe disclosure produced a large intraday share collapse and prompted additional plaintiff firms (Hagens Berman, Rosen, Block & Leviton, Frank R. Cruz, Ademi, Holzer & Holzer, Johnson Fistel, etc.) to launch or publicize investigations, increasing litigation risk and potential settlement exposure. Hagens Berman note
• Negative Sentiment: ICON pulled its 2025 outlook amid the probe and signaled potential revenue‑recognition restatements, which elevates execution risk and clouds near‑term earnings visibility — a key reason analysts and investors moved to cut exposure. Seeking Alpha

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.